It was a busy week for pharmaceutical giant Novartis
The approval of Exforge will complement Novartis' portfolio of blood pressure therapies. This portfolio grew earlier in the year with the FDA marketing approval of Tekturna. Exforge is a drug that combines its $4.2 billion Diovan and Pfizer's
The generic biologic that Novartis received a positive EU opinion on is a compound intended to be biosimilar to Amgen's
This EU recommendation is another watershed moment for the generic biopharmaceutical market, as there has been only one generic biologic approved for marketing in the EU and U.S. to date. That was another Novartis achievement last year.
For any conglomerate worth more than $100 billion, there are bound to be multiple setbacks and positive developments with its operations in any given week. Gaining regulatory approval to market a valuable blood pressure combination treatment and a future biogeneric compound in the span of two days is an achievement for any pharmaceutical company. Despite the setbacks with Galvus and Zelnorm earlier this year, this week proved that there are at least some good times ahead for Novartis.